stocktools
Offerings // BridgeBio Oncology Therapeutics, Inc.

BBOT offering history

Every offering-related filing in BridgeBio Oncology Therapeutics, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 172 filings back to Dec 20, 2023.

Last executed offering
Aug 13, 2025
8-K — priced deal (shares or notes)
Last registration (announced)
Aug 29, 2025
S-1 — capacity, not a sale
Executed, last 12 months
1
424B pricings + 8-K 3.02 sales
Registered, last 12 months
1
S-1/S-3/F-series registrations
DateFilingWhat it means
Jun 22, 2026424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
May 13, 2026424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
May 6, 2026424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
May 4, 2026EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Apr 29, 2026424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Apr 23, 2026424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Mar 26, 2026424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Mar 6, 2026424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Jan 7, 2026424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Jan 7, 2026424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Sep 10, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Sep 10, 2025EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Aug 29, 2025S-1 →REGISTEREDS-1 registration — capacity to sell shares, not a sale yet
Aug 19, 2025EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Aug 13, 20258-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Jul 22, 2025424B3 →UPDATEProspectus update — often a resale registration, not necessarily new capital
Jul 10, 2025424B4 →EXECUTEDFinal prospectus — offering priced (typical for IPOs and marketed share deals)
Jul 10, 2025EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Mar 3, 20258-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Feb 14, 20248-K →EXECUTEDUnregistered share sale disclosed (8-K item 3.02)
Feb 13, 2024424B4 →EXECUTEDFinal prospectus — offering priced (typical for IPOs and marketed share deals)
Feb 8, 2024S-1MEF →REGISTEREDS-1MEF registration — capacity to sell shares, not a sale yet
Feb 8, 2024EFFECT →EFFECTIVESEC declared a registration effective — selling can begin
Feb 7, 2024S-1/A →REGISTEREDS-1/A registration — capacity to sell shares, not a sale yet
Feb 2, 2024S-1/A →REGISTEREDS-1/A registration — capacity to sell shares, not a sale yet
Jan 18, 2024S-1 →REGISTEREDS-1 registration — capacity to sell shares, not a sale yet
BBOT offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full BBOT workspace →
BBOT offering FAQ

When did BBOT last execute an offering?

Per SEC filings, BridgeBio Oncology Therapeutics, Inc.'s most recent priced offering document is a 8-K filed 2025-08-13. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did BBOT last announce or register an offering?

The most recent registration is a S-1 filed 2025-08-29. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.